74702-94-6Relevant academic research and scientific papers
NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
-
Paragraph 0344, (2016/08/29)
The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R1 represents optionally substituted C1-4 alkyl, n shows integer of 1 to 4, R2 represents optionally substituted C1-4 alkyl or hydrogen atom, R3 represents optionally substituted C1-4 alkyl, R4a, R4b, R4c, and R4d, similarly or differently, represent optionally substituted C6-14 aryl, optionally substituted C1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].
10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE
-
Page/Page column 37, (2011/04/14)
A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
Organocerium reactions of benzamides and thiobenzamides: A direct synthesis of tertiary carbinamines
Calderwood, David J.,Davies, Roy V.,Rafferty, Paul,Twigger, Helen L.,Whelan, Helen M.
, p. 1241 - 1244 (2007/10/03)
A simple and efficient process has been developed for the direct conversion of benzamides and thiobenzamides into tertiary carbinamines. A synthesis of benzonitriles from simple benzamides and a thiobenzamide is also described.
Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses
-
, (2008/06/13)
The invention includes compounds of formula (I): STR1 in which R1 is hydrogen, alkyl, aryl-substituted alkyl or aromatic heterocyclic-substituted alkyl; R2 is aryl-substituted alkyl, aromatic heterocyclic-substituted alkyl or diarylamino; and R3 is carboxy or a group of formula --CONHSO2 R4 wherein R4 is alkyl; and pharmaceutically acceptable salts and esters of the compounds. The compounds have valuable 5α-reductase inhibitory activity and can thus be used for the treatment and prophylaxis of, inter alia, prostatic hypertrophy as well as other disorders arising from excess levels of 5α-dihydro-testosterone.
